Brisbane, United States
Freenome, founded in 2014, is a rising star in the biotech sector headquartered in the United States. The company is dedicated to early cancer detection, aiming to empower individuals in the prevention, detection, and treatment of diseases. Their slogan, "Outpacing cancer starts with early detection," encapsulates their mission to develop next-generation blood tests through a combination of multiomics platforms and machine learning techniques.
Freenome's initial product focuses on detecting early-stage colorectal cancer and advanced adenomas, positioning them as pioneers in the field of preventive oncology. To date, they have successfully raised over $1.1 billion from esteemed investors such as Perceptive Advisors, RA Capital Management, Roche Venture Fund, Kaiser Permanente, Novartis, and American Cancer Society’s BrightEdge Ventures.
The company recently secured a $75.00M late-stage VC investment from Roche in November 2025, underscoring investor confidence in their innovative approach and potential for significant impact in healthcare.
Adela, Inc.
Universal Diagnostics S.A.